MedTrace Logo

Myasthenia Gravis Inebilizumab Trial

NCT04524273 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 238

Last updated 2026-05-15

Study results available
· View outcomes & findings →

Summary

Randomized, double-blind, placebo-controlled, Phase 3, parallel-group study with optional open-label extension.

Conditions

Interventions

DRUG

inebilizumab

Participants will receive IV inebilizumab

DRUG

IV Placebo

Participants will receive IV placebo matched to inebilizumab

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2024-05-28
Completion
2029-06-07
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Belarus
  • Brazil
  • Canada
  • China
  • Denmark
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Poland
  • Russia
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • Ukraine

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04524273 on ClinicalTrials.gov